Deutsche Bank AG Reiterates “$226.00” Price Target for Thermo Fisher Scientific Inc (TMO)

Deutsche Bank AG set a $226.00 target price on Thermo Fisher Scientific Inc (NYSE:TMO) in a report released on Thursday. The brokerage currently has a buy rating on the medical research company’s stock.

Several other equities research analysts have also recently weighed in on TMO. Jefferies Group LLC reiterated a hold rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a hold rating to a buy rating and set a $197.00 target price for the company in a research note on Tuesday, August 1st. BidaskClub cut shares of Thermo Fisher Scientific from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Barclays PLC reiterated an overweight rating and issued a $200.00 target price (up previously from $190.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 17th. Finally, Wells Fargo & Company reiterated an outperform rating and issued a $200.00 target price (up previously from $195.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 13th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of Buy and an average target price of $205.50.

Shares of Thermo Fisher Scientific (NYSE TMO) traded down 3.97% during mid-day trading on Thursday, reaching $192.42. The company had a trading volume of 3,938,224 shares. Thermo Fisher Scientific has a 52-week low of $139.07 and a 52-week high of $201.20. The company has a market capitalization of $77.01 billion, a PE ratio of 33.46 and a beta of 1.05. The company’s 50-day moving average price is $191.73 and its 200-day moving average price is $178.12.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same period in the prior year, the company earned $2.03 earnings per share. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. On average, analysts forecast that Thermo Fisher Scientific will post $9.36 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.com-unik.info/2017/10/29/deutsche-bank-ag-reiterates-226-00-price-target-for-thermo-fisher-scientific-inc-tmo.html.

In related news, SVP Gregory J. Herrema sold 30,000 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $176.02, for a total value of $5,280,600.00. Following the completion of the transaction, the senior vice president now owns 67,016 shares of the company’s stock, valued at $11,796,156.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Peter E. Hornstra sold 3,894 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the completion of the transaction, the vice president now directly owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. Insiders sold 52,738 shares of company stock valued at $9,302,112 in the last three months. Company insiders own 0.49% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Waldron LP increased its holdings in shares of Thermo Fisher Scientific by 48.1% during the first quarter. Waldron LP now owns 4,455 shares of the medical research company’s stock worth $661,000 after buying an additional 1,447 shares in the last quarter. Empire Life Investments Inc. increased its holdings in shares of Thermo Fisher Scientific by 132.0% during the first quarter. Empire Life Investments Inc. now owns 52,504 shares of the medical research company’s stock worth $7,861,000 after buying an additional 29,875 shares in the last quarter. Norinchukin Bank The increased its holdings in shares of Thermo Fisher Scientific by 5.9% during the first quarter. Norinchukin Bank The now owns 25,368 shares of the medical research company’s stock worth $3,897,000 after buying an additional 1,404 shares in the last quarter. Quantitative Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth approximately $6,512,000. Finally, Campbell & CO Investment Adviser LLC increased its holdings in shares of Thermo Fisher Scientific by 46.5% during the first quarter. Campbell & CO Investment Adviser LLC now owns 3,498 shares of the medical research company’s stock worth $537,000 after buying an additional 1,110 shares in the last quarter. 83.47% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit